Curing Relapsed Follicular Lymphoma?

Most patients remain in remission a decade after chemoimmunotherapy and nonmyeloablative hematopoietic stem cell transplantation.

In a prior prospective phase II study of 47 patients with relapsed follicular lymphoma (FL), investigators showed that treatment with nonmyeloablative stem cell transplantation (SCT) after conditioning with fludarabine, cyclophosphamide, and rituximab (FCR) was effective at a median follow-up of 60 months (Blood 2008; 111:5530). Now, the researchers report updated results for these patients as well as outcomes for an additional 26 patients who underwent SCT after conditioning with ⁹⁰Yttrium-ibritumomab tiuxetan, fludarabine, and cyclophosphamide (YFC).

Patients with relapsed FL (median ages, 53–55; range 29–68) received either a single cycle of FCR or YFC followed by nonmyeloablative allogeneic hematopoietic SCT from a matched sibling or unr…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee